Genetic diversity of Collaborative Cross mice implicates FFAR3 as a target for ILC2 anti-inflammatory reprogramming

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Pulmonary group 2 innate lymphoid cells (ILC2s) are key drivers of Type 2 inflammation in diseases like asthma, yet the molecular mechanisms regulating their function are incompletely understood. Using the genetically diverse Collaborative Cross (CC) mouse panel, we mapped a quantitative trait locus (QTL) that governs ILC2 prevalence in the lung after aeroallergen exposure. This QTL induces a large population of ILC2s in the lung that are resistant to activation and have diminished Type 2 effector function. We identified free-fatty acid receptor 3 ( Ffar3 ) as a gene responsible for this effect and demonstrated that FFAR3 signaling reprograms ILC2s to an anti-inflammatory state by promoting their survival, reducing Type 2 cytokine production, and enhancing IL-10 expression. This anti-inflammatory state is dependent on IL-2 signaling, is characterized by decreased ST2 expression, and is distinct from previously described IL-10-producing ILC2 phenotypes. FFAR3-dependent reprogramming is mediated by epidermal growth factor receptor (EGFR) upregulation, and FFAR3’s anti-inflammatory effect is partially conserved in human ILC2s.
Funding Information
  • U.S. Department of Health & Human Services | National Institutes of Health (R01AI124456)
  • U.S. Department of Health & Human Services | National Institutes of Health (U19AI095227)
  • U.S. Department of Health & Human Services | National Institutes of Health (R01AI111820)
  • U.S. Department of Health & Human Services | National Institutes of Health (F30AI176712)
  • U.S. Department of Veterans Affairs (101BX004299)

This publication has 104 references indexed in Scilit: